Relmada Therapeutics (RLMD) Retained Earnings (2012 - 2026)
Relmada Therapeutics (RLMD) reported Retained Earnings of -$717.3 million for Q1 2026, down 8.94% year-over-year from -$787.8 million in Q1 2025, and down 2.73% on a QoQ basis from -$698.3 million in Q4 2025.
Relmada Therapeutics (RLMD) has 15 years of Retained Earnings data on file, last reported at -$717.3 million in Q1 2026.
- Quarterly Retained Earnings fell 8.94% year-over-year to -$717.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$717.3 million (down 8.94% YoY) and the FY2025 annual result came in at -$698.3 million, down 8.95% from the prior year.
- Retained Earnings slipped to -$717.3 million in Q1 2026 per RLMD's latest filing, from -$698.3 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$344.8 million in Q1 2022 and bottomed at -$717.3 million in Q1 2026.
- The 5-year median for Retained Earnings is -$582.7 million (2024), against an average of -$563.6 million.
- The widest annual swing landed in 2022, when Retained Earnings sank 71.1%; it then declined 8.94% in 2026.
- Tracing RLMD's Retained Earnings over 5 years: stood at -$462.1 million in 2022, then decreased by 21.38% to -$560.9 million in 2023, then retreated by 14.26% to -$640.9 million in 2024, then declined by 8.95% to -$698.3 million in 2025, then decreased by 2.73% to -$717.3 million in 2026.
- Per Business Quant, the three latest RLMD Retained Earnings figures stand at -$717.3 million (Q1 2026), -$698.3 million (Q4 2025), and -$678.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | -717.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -717.32 Mn |
| Dec 31, 2025 | -698.27 Mn |
| Sep 30, 2025 | -678.40 Mn |
| Jun 30, 2025 | -668.31 Mn |
| Mar 31, 2025 | -658.44 Mn |
| Dec 31, 2024 | -640.88 Mn |
| Sep 30, 2024 | -622.22 Mn |
| Jun 30, 2024 | -600.50 Mn |
| Mar 31, 2024 | -582.73 Mn |
| Dec 31, 2023 | -560.90 Mn |
| Sep 30, 2023 | -535.74 Mn |
| Jun 30, 2023 | -513.74 Mn |
| Mar 31, 2023 | -488.43 Mn |
| Dec 31, 2022 | -462.11 Mn |
| Sep 30, 2022 | -424.17 Mn |
| Jun 30, 2022 | -384.75 Mn |
| Mar 31, 2022 | -344.81 Mn |
| Dec 31, 2021 | -305.07 Mn |
| Sep 30, 2021 | -270.69 Mn |
| Jun 30, 2021 | -228.08 Mn |
| Mar 31, 2021 | -201.53 Mn |
| Dec 31, 2020 | -179.32 Mn |
| Sep 30, 2020 | -158.55 Mn |
| Jun 30, 2020 | -141.65 Mn |
| Mar 31, 2020 | -130.53 Mn |
| Dec 31, 2019 | -119.86 Mn |
| Sep 30, 2019 | -115.33 Mn |
| Jun 30, 2019 | -111.66 Mn |
| Mar 31, 2019 | -107.54 Mn |
| Dec 31, 2018 | -104.85 Mn |
| Sep 30, 2018 | -97.72 Mn |
| Jun 30, 2018 | -94.34 Mn |
| Mar 31, 2018 | -90.99 Mn |
| Dec 31, 2017 | -87.79 Mn |
| Sep 30, 2017 | -86.37 Mn |
| Jun 30, 2017 | -85.38 Mn |
| Mar 31, 2017 | -83.75 Mn |
| Dec 31, 2016 | -81.77 Mn |
| Sep 30, 2016 | -80.74 Mn |
| Jun 30, 2016 | -79.10 Mn |
| Mar 31, 2016 | -75.78 Mn |
| Dec 31, 2015 | -73.92 Mn |
| Sep 30, 2015 | -71.46 Mn |
| Jun 30, 2015 | -76.12 Mn |
| Mar 31, 2015 | -82.16 Mn |
| Dec 31, 2014 | -79.70 Mn |
| Sep 30, 2014 | 85.16 Mn |
| Jun 30, 2014 | -55.32 Mn |
| Nov 30, 2013 | 71,531.00 |
| Aug 31, 2013 | 57,157.00 |
| May 31, 2013 | 44,793.00 |
| Feb 28, 2013 | -25,308.00 |
| Aug 31, 2012 | 12,142.00 |